Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migrationAlja Zottel, Radovan Komel, Ivana Jovčevska et al.|Therapeutic Advances in Medical Oncology|2020Cited by 41
TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell InvasionAndrej Porčnik, Tamara Lah Turnšek, Radovan Komel et al.|Molecules|2021Cited by 29
Glioblastoma-specific anti-TUFM nanobody for <i>in-vitro</i> immunoimaging and cancer stem cell targetingNeja Šamec, Radovan Komel, Ivana Jovčevska et al.|Oncotarget|2018Cited by 28
Anti-Vimentin Nanobody Decreases Glioblastoma Cell Invasion In Vitro and In VivoAlja Zottel, Ivana Jovčevska, Metka Novak et al.|Cancers|2023Cited by 19
In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell TargetingGloria Krapež, Ivana Jovčevska, Neja Šamec et al.|Antibodies|2025Cited by 2